Lipid lowering in renal disease. - Wikidata - awgldk - TriplyDB

Lipid lowering in renal disease.

Lipid lowering in renal disease.

http://www.wikidata.org/entity/Q41690923

about

Lipid lowering in renal disease.

http://www.wikidata.org/entity/Q41690923

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Lipid lowering in renal disease.

@en

type

label

Lipid lowering in renal disease.

@en

prefLabel

Lipid lowering in renal disease.

@en

P1433

Q41690923-FFAB4B41-CAC5-4B22-9329-A4CA210FA0BE

P1476

Q41690923-2F5026EA-4CEA-44A3-927B-A008005524C9

P2093

Q41690923-59C6666E-D4B6-4054-B964-5B585E50E79F

Q41690923-84DC374F-DD25-46C2-816E-9A8D75292AEA

P2860

Q41690923-00F3981D-3702-4CE6-96A2-5591C205CE0C

Q41690923-10D40B27-07BE-4629-A274-BBDE1135D9A9

Q41690923-139B9D59-DB01-4055-BFDC-0C29E27330FC

Q41690923-1CB58B7D-55EA-4604-8ED3-A2F5E766D4A9

Q41690923-232C2FBC-8CDA-4381-B8D3-F8C29333024D

Q41690923-26A051C3-8CBF-47D1-8A77-6AD39D2DBD80

Q41690923-2B623F1B-129B-44B7-ADC0-4905C6765845

Q41690923-2D636074-12A7-4F86-850D-71BE1A0458A0

Q41690923-2E3F672D-0107-4624-A208-195A8E40F1D9

Q41690923-3761A4E3-74DC-4B67-936E-8924F20A2C19

P304

Q41690923-BE3C1650-7E61-4BC1-B2F0-2D9C1067DF7E

P31

Q41690923-7F449AE9-5D52-4CD8-A8D3-9CE707DDDEE3

P356

Q41690923-2F2C2C91-6194-4CCD-8496-F75092C065DD

P433

Q41690923-AF62FEBE-C945-4F3A-BEBD-31F85A574885

P478

Q41690923-0F6B2712-97F7-4D50-96F3-0199DE3A8461

P577

Q41690923-44F7EA1A-99D9-4631-9B54-64848292F9EE

P698

Q41690923-85D19321-0999-4FB4-A41E-BB717A81D37E

P932

Q41690923-D30FCBF5-B39D-4FF5-95E9-6C62E55BED90

P356

AUSTPRESCR.2017.047

P1433

Australian Prescriber

P1476

Lipid lowering in renal disease.

@en

P2093

Alice Kennard

http://www.w3.org/2001/XMLSchema#string

Richard Singer

http://www.w3.org/2001/XMLSchema#string

P2860

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

Effects of fibrates in kidney disease: a systematic review and meta-analysis

Lipid abnormalities in kidney disease and management strategies

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Chronic kidney disease and mortality risk: a systematic review

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

P304

141-146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18773/AUSTPRESCR.2017.047

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28947852

http://www.w3.org/2001/XMLSchema#string

P932

5601972

http://www.w3.org/2001/XMLSchema#string